(NASDAQ: BNTX) Biontech Se's forecast annual revenue growth rate of -6.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 117.27%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 22.74%.
Biontech Se's revenue in 2025 is $3,665,697,674.On average, 25 Wall Street analysts forecast BNTX's revenue for 2026 to be $658,607,477,550, with the lowest BNTX revenue forecast at $431,377,077,300, and the highest BNTX revenue forecast at $875,017,382,550. On average, 22 Wall Street analysts forecast BNTX's revenue for 2027 to be $672,553,893,650, with the lowest BNTX revenue forecast at $421,758,859,300, and the highest BNTX revenue forecast at $917,818,452,650.
In 2028, BNTX is forecast to generate $736,034,132,450 in revenue, with the lowest revenue forecast at $415,747,473,050 and the highest revenue forecast at $1,166,208,932,500.